Navigation Links
TrialNetworks Feasibility Survey™ App Gets ARIAD Pharmaceuticals Unprecedented 75% Response from Potential Clinical Trial Investigator Sites
Date:9/30/2013

(PRWEB) September 30, 2013

TrialNetworks reported that ARIAD Pharmaceuticals, Inc. streamlined clinical trial site selection with a 75% response rate from potential sites located in 15 countries for a pivotal Phase II oncology study, besting the gold standard response by 25%. ARIAD chose to implement TrialNetworks Feasibility Survey because the online app makes collecting structured information from potential or existing sites quick, efficient and pain-free. In addition, Feasibility Survey integrates with other apps in the TrialNetworks platform to ensure a seamless transition from feasibility to site activation, training, document management, and the entire study startup process.

The majority of feasibility surveys are conducted inefficiently – often using paper, standard office spreadsheet programs or, at best, broad consumer survey software – typically yielding illegible, illogical, delayed and incomplete responses. This places a significant burden on the sponsor and CRO study teams to manually track non-responses, chase domestic and global sites to fill in missing or incorrect answers, and attempt to analyze responses across multiple versions of inconsistent formats.

Feasibility Survey solves these challenges by enabling sponsors to deploy secure, intelligently designed and easy-to-use surveys which guide study coordinators through survey completion, ensuring all questions are appropriately answered. Response options are formatted as clear, interactive fields (e.g. multiple choice, ranking tasks, free text, etc.) and can include text or video to guide respondents and encourage completion. Email reminders, custom alerts and detailed reporting provides sponsors with transparency into the survey progress so they can follow up efficiently with key sites yet to respond.

ARIAD, headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines.

Jeff Davis, Associate Director, Clinical Operations at ARIAD Pharmaceuticals, said, “ARIAD enjoys a strong collaboration with TrialNetworks and we were highly encouraged by the response we received using Feasibility Survey. Integrating these assessments into the rest of the platform ensures we realize the full benefits of TrialNetworks including more efficient processes, reduced time and cost, and a welcoming site experience. TrialNetworks technology makes it easy for sites to provide ARIAD with reliable information which we will use to make critical site selection decisions, and gives us clear visibility into and more control over global clinical operations than ever before.”

To prepare for the selection process, ARIAD sent the TrialNetworks Feasibility Survey to nearly 300 sites globally and received 225 responses – a huge accomplishment, says ARIAD Clinical Trial Manager Jay Pietrantonio: “The gold standard is to receive 50% of surveys back. To get 75% back is extremely impressive. The TrialNetworks Feasibility Survey app enabled ARIAD to meet our aggressive timeline for site selection by quickly identifying sites we are confident will enroll and exceed expectations in this pivotal trial.”

The TrialNetworks platform is the industry’s only Clinical Trial Optimization System proven to improve results from startup through closeout – including feasibility, site activation, patient recruitment and retention, site engagement and conduct – all from one centralized interface.

Eric Silberstein, CEO of TrialNetworks, said, “We are thrilled to partner with forward-thinking customers such as ARIAD who seek innovative solutions to make clinical operations more efficient. Equipping operations teams and sites with modern and efficient technology from feasibility through to closeout is becoming a critical success factor for sponsors and CROs.”

To discover how the TrialNetworks platform is revolutionizing clinical trial optimization, request a demo at http://www.trialnetworks.com.

About TrialNetworks

TrialNetworks provides sponsors and CROs, the industry's only Clinical Trial Optimization System. Using modern and intuitive technology, the TrialNetworks platform increases the quality and efficiency of clinical operations at each stage of a trial from feasibility through closeout. TrialNetworks apps, including Checklist, Document Library, Visit Guide, Action Items and Directory, are available in a unified and secure cloud-based interface. Customers ranging from top-10 pharmaceutical companies to biotechs have implemented the TrialNetworks platform for use in Phase I-IV studies by more than 20,000 site staff in 60 countries. To learn why sponsors rely on TrialNetworks to optimize clinical trial operations, request a demo at http://www.trialnetworks.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11164654.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. TrialNetworks Customer to Present Results of Using Site Engagement Technology to Improve Study Operations and Patient Enrollment at Clinical Trial Optimization Conference
2. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
(Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
Breaking Biology News(10 mins):